2017年5月
Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era
INTERNATIONAL JOURNAL OF HEMATOLOGY
- 巻
- 105
- 号
- 5
- 開始ページ
- 658
- 終了ページ
- 667
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1007/s12185-016-2166-0
- 出版者・発行元
- SPRINGER JAPAN KK
Disease-specific cytogenetic abnormalities involving BCL2 gene rearrangement frequently co-exist with other cytogenetic abnormalities, contributing to disease progression in follicular lymphoma (FL). In the present study, we retrospectively investigated the prognostic impact of BCL2-unrelated cytogenetic abnormalities in FL. Of 139 consecutively diagnosed patients with FL at two independent institutes, metaphase spreads of tumor cells were obtained for use in G-banding analysis in 77 patients. The recurrent additional cytogenetic abnormalities included chromosome gains +5 (n = 8), +7 (n = 16), +12 (n = 10), and +X (n = 12), and losses -8 (n = 7), -13 (n = 12) -15 (n = 7), and 6q- (n = 7). While -15 was associated with shorter progression-free survival (PFS) in all 77 analyzed patients with evaluable G-banding results (p = 0.04), this negative impact was not evident in 42 patients treated using an R-CHOP-like regimen as first-line treatment. By contrast, 6q- was predictive for shorter PFS in patients who were initially treated with R-CHOP-like regimens without maintenance therapy (p < 0.01), while this negative impact was not evident in all 77 patients with evaluable G-banding results. These results suggest the presence of a molecular region in chromosome 6q that is responsible for the shorter PFS following R-CHOP-like chemotherapy.
- リンク情報
- ID情報
-
- DOI : 10.1007/s12185-016-2166-0
- ISSN : 0925-5710
- eISSN : 1865-3774
- PubMed ID : 27995457
- Web of Science ID : WOS:000399895700015